NasdaqCM:OBXBiotechs
Obsidian Therapeutics (OBX) Reached A Trial Milestone, Does The Valuation Already Look Full?
Why Obsidian Therapeutics Stock Is Back in Focus After New Trial Milestone
Obsidian Therapeutics (OBX) is drawing fresh attention after enrolling the first patient in a registration enabling cohort of its Phase 1/2 Agni-01 trial for amsoki-cel in advanced melanoma.
See our latest analysis for Obsidian Therapeutics.
The trial milestone comes after a sharp rebound in Obsidian Therapeutics’ share price, with a 1 day share price return of 27.27% and a year to date share price return of 435.22%...